Gene Mannheimer

Analyst Gene Mannheimer of Auriga downgraded athenahealth (NASDAQ: ATHN) from “buy” to “hold,” while revising his estimates for the company. The 12-month target price for ATHN has been reduced from $32 to $30. ATHN has posted its quarterly EPS ahead of and revenues short of the estimates and the...

Auriga analyst Gene Mannheimer upgraded Omnicell (NASDAQ: OMCL) to Buy. Omnicell is a company specializing in medication and supply dispensing systems for the healthcare industry. According to Auriga, "We believe the company won a new Supply contract at Scott & White Hospital: Though yet...

Analyst Gene Mannheimer at Auriga has released an update on McKesson Corporation (NYSE: MCK). The company has announced a $1 billion stock buyback program. According to Auriga, the announcement gives a message that the company believes it can generate greater shareholder value by deploying its...

Auriga analyst Gene Mannheimer reiterated his Buy rating for shares of inVentiv Health Inc. (NASDAQ: VTIV), with a price target of $27 per share. Mannheimer was looking forward to inVentiv Health Inc. reporting its financial results after the market closes today and said that he believed the...

Auriga analyst Gene Mannheimer reiterated his Buy rating for shares of Eclipsys Corporation (NASDAQ: ECLP), with a price target of $24. Mannheimer noted that Eclipsys Corporation recently reported mixed financial results, beating Auriga's earnings estimates, while missing the revenue forecast. The...

Analyst Gene Mannheimer at Auriga has released an update on eResearch Technology, Inc. (NASDAQ: ERES). Last week, the company reported its first-quarter results. The company also announced its acquisition of the Clinical Research Services division of CareFusion (NYSE: CFN). eResearch’s first-...

Auriga analyst Gene Mannheimer reiterated a Hold rating for shares of Athenahealth, Inc (NASDAQ: ATHN) and reduced the price target to $32 per share from the previous price target of $40 per share. The reduced price target follows the release of financial results by Athenahealth, Inc that failed to...

Analyst Gene Mannheimer at Auriga has raised the price target for Cerner Corporation (NASDAQ: CERN) from $85 to $87. The company reported its first-quarter results on Wednesday. Cerner reported first-quarter EPS of $0.63, compared with Auriga’s estimate of $0.60 and consensus of $0.61. Revenue...

Analyst Gene Mannheimer at Auriga has released a report reviewing the fourth-quarter results at MedAssets, Inc. (NASDAQ: MDAS). The company reported EPS of $0.28 on revenue of $95.7 million for the quarter. Auriga estimated EPS of $0.26 on revenue of $96 million, while the consensus EPS estimate...